Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement: the complexity of the elderly.

ABSTRACT: Along with epidemiologic transitions of the global population, the burden of aortic stenosis (AS) is rapidly increasing and transcatheter aortic valve replacement (TAVR) has quickly spread; indeed, it is nowadays also employed in treating patients with AS at intermediate operative risk. Nonetheless, the less invasive interventional strategy still carries relevant issues concerning post-procedural optimal antithrombotic strategy, given the current indications provided by guidelines are not completely supported by evidence-based data. Geriatric patients suffer from high bleeding and thromboembolic risks, whose balance is particularly subtle due to the presence of concomitant conditions, such as atrial fibrillation and chronic kidney disease, that make the post-TAVR antithrombotic management

SUBMITTER: Bencivenga L 

PROVIDER: S-EPMC7665487 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature